A survey on diarrhea and convenience of intake associated with a single-dose extended release formulation of azithromycin

Pharmazie

Volumn 66, Issue 3, 2011, Pages 226-229

  Okayasu, S ^a   Matsuura, K ^a   Kondoh, Y ^b   Tsuruta, E ^c   Takashima, E ^d   Suzuki, M ^c   Nagai, T ^c   Yasuda, K ^a   Itoh, Yoshinori ^a  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b Phain Pharmacy   (Japan)

^c GIFU UNIVERSITY   (Japan)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; ASIAN; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HOSPITAL PHARMACY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; QUESTIONNAIRE; SINGLE DRUG DOSE; TASTE; UNPLEASANT BITTER TASTE; AGED; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DELAYED RELEASE FORMULATION; INFORMATION PROCESSING; JAPAN; MIDDLE AGED; PATIENT SATISFACTION; PHARMACY;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHEMISTRY, PHARMACEUTICAL; COMMUNITY PHARMACY SERVICES; DATA COLLECTION; DELAYED-ACTION PREPARATIONS; DIARRHEA; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHARMACY SERVICE, HOSPITAL; QUESTIONNAIRES;

EID: 79957531383     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0712     Document Type: Article

References (20)

1. Amrol D (2007) Single-dose azithromycin microsphere formulation: a novel delivery system for antibiotics. Int J Nanomedicine 2: 9-12.
2. Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40: 1-15.
3. Cooper MA, Nye K, Andrews JM, Wise R (1990) The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 26: 533-538. (Pubitemid 20346869)
4. Drehobl MA, De Salvo MC, Lewis DE, Breen JD (2005) Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128: 2230-2237. (Pubitemid 41507564)
5. Fang AF, Palmer JN, Chiu AG, Blumer JL, Crownover PH, Campbell MD, Damle BD (2009) Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis. Int J Antimicrob Agents 34: 67-71.
6. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D (1994) Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 21:107-111. (Pubitemid 24127677)
7. Higa F, Saito A (2000) Clinical safety of azithromycin. Jpn J Antibiot 53 (Suppl B): 125-135.
8. Hooker KD, DiPiro JT (1988) Effect of antimicrobial therapy on bowel flora. Clin Pharm 7: 878-888. (Pubitemid 19020744)
9. Hopkins S (1991) Clinical toleration and safety of azithromycin. Am J Med 91: 40S-45S.
10. Jorgensen DM (2009) Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A beta-haemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: a double-blind, double-dummy study. Clin Microbiol Infect 15: 1103-1110.
11. Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD, Sharma A (2007) Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 51: 103-109. (Pubitemid 46047694)
12. Lo JB, Appel LE, Herbig SM, McCray SB, Thombre AG (2009) Formulation design and pharmaceutical development of a novel controlled release form of azithromycin for single-dose therapy. Drug Dev Ind Pharm 35: 1522-1529.
13. Marple BF, Roberts CS, de Caprariis PJ, Reisman A (2007) Onset of symptom resolution in adults with acute bacterial rhinosinusitis treated with a single dose of azithromycin extended release compared with 10 days of levofloxacin: a retrospective analysis of a randomized, double-blind, double-dummy trial. Clin Ther 29: 2690-2698.
14. Mick P, Westerberg BD (2007) Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin. J Otolaryngol 36: 257-263. (Pubitemid 350114705)
15. Oberg K, Theodorsson-Norheim E, Norheim I (1987) Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 22: 1041-1048. (Pubitemid 17156994)
16. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749-1756. (Pubitemid 37430625)
17. von Rosensteil NA, Adam D (1995) Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 13: 105-122.
18. Whitman MS, Tunkel AR (1992) Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol 13: 357-368.
19. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G (2007) Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 29: 56-61. (Pubitemid 44959787)
20. Zgoulli S, Grek V, Barre G, Goffinet G, Thonart P, Zinner S (1999) Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. J Microencapsul 16: 565-571. (Pubitemid 29403554)